Published in Hepatology on February 01, 2006
Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology (2007) 2.72
Impact of the hepatopulmonary syndrome MELD exception policy on outcomes of patients after liver transplantation: an analysis of the UNOS database. Gastroenterology (2014) 2.15
MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut (2007) 2.09
Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era. Hepatology (2011) 2.01
Association of distance from a transplant center with access to waitlist placement, receipt of liver transplantation, and survival among US veterans. JAMA (2014) 1.95
Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant (2007) 1.70
Serum sodium, renal function, and survival of patients with end-stage liver disease. J Hepatol (2010) 1.62
Rationale and design of the pediatric critical illness stress-induced immune suppression (CRISIS) prevention trial. JPEN J Parenter Enteral Nutr (2009) 1.58
Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis. Liver Transpl (2013) 1.52
Competing risks survival analysis applied to data from the Australian Orthopaedic Association National Joint Replacement Registry. Acta Orthop (2010) 1.46
Role of magnetic resonance elastography in compensated and decompensated liver disease. J Hepatol (2013) 1.20
Height contributes to the gender difference in wait-list mortality under the MELD-based liver allocation system. Am J Transplant (2010) 0.99
Impact of MELD on waitlist outcome of retransplant candidates. Am J Transplant (2010) 0.91
Liver Transplantation: East versus West. J Clin Exp Hepatol (2013) 0.89
Overview of the indications and contraindications for liver transplantation. Cold Spring Harb Perspect Med (2014) 0.87
Patients With Hepatocellular Carcinoma Have Highest Rates of Wait-listing for Liver Transplantation Among Patients With End-Stage Liver Disease. Clin Gastroenterol Hepatol (2016) 0.87
In vitro culture of isolated primary hepatocytes and stem cell-derived hepatocyte-like cells for liver regeneration. Protein Cell (2015) 0.83
Liver progenitor cell line HepaRG differentiated in a bioartificial liver effectively supplies liver support to rats with acute liver failure. PLoS One (2012) 0.80
Reframing the impact of combined heart-liver allocation on liver transplant wait-list candidates. Liver Transpl (2014) 0.79
Survival of patients with alcoholic and cryptogenic cirrhosis without liver transplantation: a single center retrospective study. BMC Res Notes (2012) 0.79
Liver transplantation for malignancy: current treatment strategies and future perspectives. World J Gastroenterol (2014) 0.78
Stem cell-based regenerative opportunities for the liver: State of the art and beyond. World J Gastroenterol (2015) 0.77
Metabolic profiling during ex vivo machine perfusion of the human liver. Sci Rep (2016) 0.77
Warm ischemic injury is reflected in the release of injury markers during cold preservation of the human liver. PLoS One (2015) 0.77
Chemoembolization decreases drop-off risk of hepatocellular carcinoma patients on the liver transplant list. Cardiovasc Intervent Radiol (2010) 0.76
Autologous bone marrow-derived cells in the treatment of liver disease patients. Saudi J Gastroenterol (2015) 0.75
Predicting Outcomes on the Liver Transplant Waiting List in the United States: Accounting for Large Regional Variation in Organ Availability and Priority Allocation Points. Transplantation (2016) 0.75
Pushing the boundaries in liver graft utilisation in transplantation: Case report of a donor with previous bile duct injury repair. Int J Surg Case Rep (2017) 0.75
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc (2003) 9.96
A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med (2002) 8.63
Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med (2006) 7.24
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology (2007) 6.68
Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med (2008) 6.67
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med (2007) 6.07
Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet (2010) 4.75
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood (2005) 4.48
Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl (2005) 4.46
POEMS syndrome: definitions and long-term outcome. Blood (2002) 4.35
Mechanisms of hepatotoxicity. Toxicol Sci (2002) 4.13
Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology (2008) 3.95
Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum (2010) 3.84
Diagnosis and management of primary sclerosing cholangitis. Hepatology (2010) 3.60
Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem (2006) 3.57
Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology (2006) 3.52
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol (2004) 3.43
Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol (2009) 3.42
Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol (2011) 3.36
Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology (2004) 3.23
Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology (2003) 3.22
Cholangiocarcinoma. Gastroenterology (2005) 3.15
Cellular and molecular mechanisms of liver injury. Gastroenterology (2008) 3.02
Lysosomes in cell death. Oncogene (2004) 3.00
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood (2004) 2.97
Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis (2008) 2.89
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene (2005) 2.89
Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology (2003) 2.89
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood (2007) 2.87
Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology (2013) 2.81
Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin Gastroenterol Hepatol (2011) 2.74
Apoptosis: the nexus of liver injury and fibrosis. Hepatology (2004) 2.70
Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood (2003) 2.68
Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. Liver Transpl (2015) 2.63
Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc (2004) 2.62
Serum aminotransferase activity and mortality risk in a United States community. Hepatology (2008) 2.61
EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma. Gastrointest Endosc (2007) 2.61
Survival differences following lung transplantation among US transplant centers. JAMA (2010) 2.57
Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest (2012) 2.56
Dental procedures as risk factors for prosthetic hip or knee infection: a hospital-based prospective case-control study. Clin Infect Dis (2010) 2.54
Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 2.51
Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology (2003) 2.45
Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology (2012) 2.44
Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation (2007) 2.43
Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc (2004) 2.43
Life and death by death receptors. FASEB J (2009) 2.39
Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology (2007) 2.36
Cholangiocarcinoma. Clin Liver Dis (2008) 2.33
Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology (2012) 2.33
Faster cyclic loess: normalizing RNA arrays via linear models. Bioinformatics (2004) 2.31
Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades. Cancer (2004) 2.31
Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest (2014) 2.31
Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol (2003) 2.29
The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum (2007) 2.25
Sudden death after myocardial infarction. JAMA (2008) 2.24
Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg (2005) 2.23
Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg (2009) 2.23
A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol (2004) 2.23
MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology (2009) 2.23
Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol (2006) 2.19
Hepatocyte death: a clear and present danger. Physiol Rev (2010) 2.18
Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis (2005) 2.18
High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum (2008) 2.14
Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis (2008) 2.12
3' tag digital gene expression profiling of human brain and universal reference RNA using Illumina Genome Analyzer. BMC Genomics (2009) 2.12
Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res (2008) 2.07
The association between age and nephrosclerosis on renal biopsy among healthy adults. Ann Intern Med (2010) 2.06
Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest (2006) 2.03
Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology (2005) 2.03
Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology (2013) 2.03
Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. J Rheumatol (2008) 2.02
Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis (2011) 2.01
Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. J Biol Chem (2007) 2.01
Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (2011) 2.01
Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut (2007) 1.99
A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation. Gastroenterology (2011) 1.99
Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood (2006) 1.98
Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology (2002) 1.98
Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. J Clin Invest (2010) 1.97
Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest (2003) 1.96
MELD is superior to King's college and Clichy's criteria to assess prognosis in fulminant hepatic failure. Liver Transpl (2007) 1.94
The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. Arthritis Rheum (2008) 1.94
The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum (2011) 1.91
Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res (2004) 1.91